What to expect in the Structure Therapeutics Inc. interview process

Based on publicly available sources, Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage, science-driven global biopharmaceutical company headquartered at Gateway Boulevard in South San Francisco, California, with a presence in China and a globally distributed workforce across seven countries (including the United States, United Kingdom, Netherlands, Canada, and China).

The company has experienced rapid headcount expansion. Public records show its annual employee count grew from 68 employees in 2022 to 93 in 2023, 163 in 2024, and approximately 220 to 233 employees between 2025 and 2026. This scaling accompanies active clinical programs for oral small molecule treatments—such as aleniglipron and GSBR-1290—targeting chronic metabolic and cardiopulmonary conditions, positioning the firm to compete with industry giants like Novo Nordisk and Eli Lilly in weight-loss therapeutics.

Leadership updates highlight ongoing organizational scaling, including the 2025 appointments of Marc Navre as Senior Vice President of Head of Biology, Belen Carrillo-Rivas as Senior Vice President of Regulatory Affairs & Quality, and the April 2026 appointment of Matthew Lang as Chief Operating Officer and General Counsel. Executive compensation filings show top-tier leadership structures led by CEO Raymond C. Stevens ($1.19M), alongside other key executives including CFO Jun S. Yoon, CSO Xichen Lin, CMO Blai Coll, and CTO Yingli Ma. The company maintains a market capitalization of approximately $3.58B with $2B in total funding across eight prior rounds, reflecting a well-capitalized yet mid-sized biotech operating environment.